Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study

被引:76
作者
Saran, R
Novak, JE
Desai, A
Abdulhayoglu, E
Warren, JS
Bustami, R
Handelman, GJ
Barbato, D
Weitzel, W
D'Alecy, LG
Rajagopalan, S
机构
[1] Univ Michigan, Kidney Epidemiol & Cost Ctr, Div Nephrol, Ann Arbor, MI 48103 USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48103 USA
[3] Univ Michigan, Dept Physiol, Ann Arbor, MI 48103 USA
[4] Univ Michigan, Dept Cardiovasc Med, Ann Arbor, MI 48103 USA
[5] Univ Renal Res & Educ Inst, Ann Arbor, MI USA
[6] Univ Massachusetts Lowell, Boston, MA USA
关键词
asymmetric dimethylarginine (ADMA); chronic kidney disease; isoprostane; nitric oxide; alpha-tocopherol; vitamin E;
D O I
10.1093/ndt/gfg406
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase and a proposed cardiovascular risk factor, is elevated in chronic kidney disease (CKD). Pharmacological strategies that lower plasma concentration of ADMA may be expected to increase nitric oxide (NO.) bioavailability and potentially limit atherosclerosis. We hypothesized that the antioxidant alpha-tocopherol (vitamin E) reduces ADMA levels in CKD. Methods. An open-label pilot interventional study using 800 IU of vitamin E was undertaken in eight stable out-patients with non-diabetic CKD (creatinine clearance < 30ml/min/1.73 m(2)) and six healthy controls, with the objective of measuring plasma ADMA levels at baseline and after 8 weeks of treatment. Plasma ADMA, symmetric dimethylarginine (SDMA) and alpha-tocopherol concentrations were determined at study entry and exit using high-performance liquid chromatography, while plasma total F2-isoprostanes, an index of oxidative stress, were measured using a commercially available enzyme-linked immunosorbent assay kit. Results. ADMA and SDMA concentrations were significantly higher in the plasma of patients compared with that of controls (P <= 0.001). After treatment with vitamin E, ADMA decreased by 23% in six of eight patients (P < 0.001). The remaining two patients showed either an increase or no change (overall, P = 0.16). There was no significant change in plasma F2-isoprostanes with vitamin E treatment for 8 weeks. Conclusions. Antioxidant therapy with vitamin E has the potential to lower ADMA levels in CKD patients, implying increased NO. availability. This strategy merits further exploration in the setting of CKD prior to renal replacement.
引用
收藏
页码:2415 / 2420
页数:6
相关论文
共 20 条
[1]  
Anderstam B, 1997, J AM SOC NEPHROL, V8, P1437
[2]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[3]   LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells -: Involvement of S-adenosylmethionine-dependent methyltransferases [J].
Böger, RH ;
Sydow, K ;
Borlak, J ;
Thum, T ;
Lenzen, H ;
Schubert, B ;
Tsikas, D ;
Bode-Böger, SM .
CIRCULATION RESEARCH, 2000, 87 (02) :99-105
[4]   Elevated plasma levels of F2α isoprostane in cystic fibrosis [J].
Collins, CE ;
Quaggiotto, P ;
Wood, L ;
O'Loughlin, EV ;
Henry, RL ;
Garg, ML .
LIPIDS, 1999, 34 (06) :551-556
[5]   Does ADMA cause endothelial dysfunction? [J].
Cooke, JP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (09) :2032-2037
[6]   Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients [J].
Fleck, C ;
Janz, A ;
Schweitzer, F ;
Karge, E ;
Schwertfeger, M ;
Stein, G .
KIDNEY INTERNATIONAL, 2001, 59 :S14-S18
[7]   Vitamin E as a protective antioxidant in progressive renal failure [J].
Fryer, MJ .
NEPHROLOGY, 2000, 5 (1-2) :1-7
[8]   The antioxidant paradox [J].
Halliwell, B .
LANCET, 2000, 355 (9210) :1179-1180
[9]   ORAL ALPHA-TOCOPHEROL SUPPLEMENTS DECREASE PLASMA GAMMA-TOCOPHEROL LEVELS IN HUMANS [J].
HANDELMAN, GJ ;
MACHLIN, LJ ;
FITCH, K ;
WEITER, JJ ;
DRATZ, EA .
JOURNAL OF NUTRITION, 1985, 115 (06) :807-813
[10]   Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy [J].
Islam, KN ;
O'Byrne, D ;
Devaraj, S ;
Palmer, B ;
Grundy, SM ;
Jialal, I .
ATHEROSCLEROSIS, 2000, 150 (01) :217-224